Ignite Creation Date:
2025-12-24 @ 2:05 PM
Ignite Modification Date:
2025-12-27 @ 10:45 PM
Study NCT ID:
NCT05223595
Status:
UNKNOWN
Last Update Posted:
2022-02-04
First Post:
2022-01-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-02
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-01-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-04
First Submit QC Date:
None
Study First Post Date:
2022-02-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-01-24
Last Update Post Date:
2022-02-04
Last Update Post Date Type:
ACTUAL